Pharmaceutical manufacturer for Riboflavin

Harman Finochem Limited is an India-based Pharmaceutical Company catering to its clients across the globe. Established by Mr. Bhupinder Singh Manhas in 1983, our core competencies are in manufacturing and exporting of Active Pharmaceutical Ingredients mainly Metformin HCl, Fenofibrate, Divalproex Sodium, Riboflavin Phosphate Sodium, Glycopyrrolate/Glycopyrronium bromide and more.

We are utilizing the world's top-level fermentation and synthesis technologies to supply domestic and overseas users with various fine chemical products centered on amino and nucleic acids for pharmaceuticals, nutritional supplements, and industrial use, as well as the derivatives of such acids. Through the rapid progress in genome analysis seen in recent years, we anticipate the development of new biotechnology processes and products from fermentation, a technology which humankind has been utilizing since time immemorial.

Rochem International, Inc. has been a prominent distributor of pharmaceutical, food, nutritional, and animal health ingredients since its establishment in 1994. It procures top-notch ingredients produced in China. With its headquarters in Hauppauge, New York, Rochem operates 16 global offices to meet its clients' requirements. The company's activities adhere to cGMP standards and have undergone audits by the USFDA and various multinational entities. Furthermore, it provides training and conducts audits for its partners to ensure FDA compliance for their technologies and systems.

Minsheng Group Shaoxing Pharmaceutical Co., Ltd.（herein after called Minsheng), located in Shaoxing city, China. With its extensive expertise and advanced facilities, Minsheng specializes in manufacturing APIs. Minsheng is the subsidiary of Hangzhou Minsheng Pharmaceutical Holding Group Co.,Ltd. which has nearly 100 years history. Covering a total area of 235,000M2, Minsheng has nearly 500 employees. More than 30% of these professionals are specialized technical personnel. Minsheng primarily manufactures over 30 types of APIs, with approximately 50% of the output being exported. Nine products have obtained US FDA approval , two products have acquired EU CEP, one product has received recognition from Japan PMDA, and one product has listed in WHO PQ. Minsheng possesses extensive experience in collaborating with big pharma. Companies. Minsheng pays much attention on regulatory compliance including but not limited to GMP and EHS. Minsheng also focus on R&D new projects, fully support all innovation ideas & execution. Minsheng has a new plant site in a specialized Chemical Park, Shangyu city. Minsheng now is embracing new projects and larger development.